Status: Recruiting
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Participants needed: 46
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Jun 11, 2026Locations: 345
Eligibility criteria
Participants must have a pathologically-confirmed diagnosis of non-small cell lu... [+41]